Genmab presents full data set for cancer drug

In April, the biotech firm released topline results from a phase II study of its treatment for large B-cell lymphoma, epcoritamab, and Genmab has now revealed the full picture.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
by marketwire, translated by daniel pedersen

On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading